SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.” The collaborative research with Oregon Health & Science University (OHSU) sheds light on the phenomenon occurring on Biological Dynamics’ ExoVerita platform that allows for the capture of biomarkers carried by nanoscale particles.
Extracellular vesicles, including exosomes, are naturally released from cells into the bloodstream and carry cellular biomarkers that can be specific for a variety of different diseases, including cancer. Detecting and recovering exosomes to analyze the biomarkers they carry has been a challenge due to their low levels, small sizes, and low buoyant density.
“This publication further supports our novel technology and its ability to successfully isolate exosomes circulating in the blood, providing valuable information about people’s health that may lead to early disease detection,” said Paul R. Billings, MD, Ph.D., CEO and Director of Biological Dynamics.
Biological Dynamics’ proprietary lab-on-a-chip platform leverages AC Electrokinetics (ACE) technology for the isolation of exosomes from undiluted biofluids, such as whole blood, plasma, and serum.
The research, led by Dr. Stuart D. Ibsen, Ph.D. at OHSU, and Juan Pablo Hinestrosa, Ph.D., VP of Research at Biological Dynamics, was prompted by the desire to further the understanding of the technology and its ability to isolate biomarkers. The findings are key to applications such as liquid biopsy tests where increasing the collection of cancer-derived exosomes is crucial for improved sensitivity.
“Isolating exosomes has been a major constraint on the advancement of exosome-based research,” said Dr. Hinestrosa. “Our findings reinforce the impact our technology has on the ability to collect biologically derived nanoparticles from undiluted high-conductance media.”
"This is a major step forward in understanding how to achieve enhancement of electrokinetic based nanoparticle collection," said Dr. Ibsen. "I look forward to seeing how the advancements we make with the technique improve the capability of diagnostic tools to detect and analyze diseases."
About Biological Dynamics
Biological Dynamics, Inc. is a leader in exosome-isolation technology committed to improving global health outcomes by identifying early-stage disease. Its ExoVerita™ platform offers a simple and automated workflow to enrich for exosomes, powering advanced detection tests for some of the most challenging diseases. Biological Dynamics’ ExoVita™ assays utilize the ExoVerita platform to enable reliable surveillance and early cancer detection to help enhance and extend lives. The Company operates a CAP-accredited, CLIA-certified clinical laboratory in San Diego, California. Learn more at www.BiologicalDynamics.com.
